Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 14, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Brian Abrahams Reiterated (BCRX) at Hold and Held Target at $10 on, Mar 14th, 2023
Brian Abrahams of RBC Capital, Reiterated "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold and Held Target at $10 on, Mar 14th, 2023.
Brian has made no other calls on BCRX in the last 4 months.
There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 0 agree with Brian's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Brian
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $30 on, Wednesday, February 22nd, 2023
- Jonathan Wolleben of "JMP Securities" Reiterated at Buy and Held Target at $16 on, Wednesday, February 22nd, 2023
- Serge Belanger of "Needham" Upgraded from Hold to Strong Buy and Held Target at $14 on, Wednesday, February 22nd, 2023
